Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01605227 · ClinicalTrials.gov registry record · Phase 3

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

A Phase 3 study of Prostate Cancer and Pain, sponsored by Exelixis.

Completed
Registry status
Phase 3
Development phase
1,028
Enrollment target
20
Study locations

NCT01605227 is a Phase 3 study of Prostate Cancer and Pain that has completed, run by Exelixis. The registered enrollment target is 1,028 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01605227, a Phase 3 study of Prostate Cancer and Pain, has completed, sponsored by Exelixis.

COMPLETED
Registry status
Phase 3
Development phase
1,028 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.

Conditions Studied

Prostate Cancer Pain Prostatic Neoplasms Castration-resistant Prostate Cancer

Interventions

  • DRUG prednisone
  • DRUG cabozantinib

Study Locations (20)

California

  • - Duarte
  • - Highland
  • - La Jolla
  • - Los Angeles
  • - Montebello
  • - Orange
  • - Palo Alto
  • - Rancho Mirage
  • - San Marcos
  • - St. Helena
  • - Vallejo

Arizona

  • - Phoenix
  • - Scottsdale
  • - Tucson

Connecticut

  • - New Haven
  • - Southington

Alabama

  • - Birmingham

Alaska

  • - Anchorage

Arkansas

  • - Jonesboro

Colorado

  • - Aurora

Trial Details

FieldValue
Enrollment Target 1,028 participants
Start Date 2012-07
Est. Completion 2015-03
Phase Phase 3

Sponsor

Exelixis

48 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01605227

The ClinicalTrials.gov registry entry for NCT01605227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,028 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which prednisone is the first listed.

NCT01605227 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01605227 about?

NCT01605227 is a clinical study titled "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100". This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MD...

What is the current status of trial NCT01605227?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,028 participants. The study started on 2012-07. Estimated completion is 2015-03.

What conditions does trial NCT01605227 study?

This clinical trial studies the following conditions: Prostate Cancer, Pain, Prostatic Neoplasms, Castration-resistant Prostate Cancer.

What interventions are being tested in trial NCT01605227?

The interventions under investigation include: prednisone (DRUG), cabozantinib (DRUG).

Who is sponsoring clinical trial NCT01605227?

This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01605227 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Pain

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.